Business
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report
WALTHAM, Mass., March 10, 2026--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial Resistance (AMR) Benchmark Report published by the Access to Medicine Foundation. The score represents the highest rating in the small- and medium-sized enterprise (SME) category, achieved by only one other company in this year’s report. The AMR Benchmark evaluates phar
About this update from Innoviva, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/539e51da8e1d6f07b720e522e15ccb98"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IUPn0X.3N0EkXYdhnsUuQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/539e51da8e1d6f07b720e522e15ccb98","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/CJljO3IaW.gJUoZPJVNFcw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/539e51da8e1d6f07b720e522e15ccb98","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Report Highlights the Company’s Collaboration with GARDP to Develop NUZOLVENCE® (zoliflodacin) for Oral Suspension for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Pediatric Patients","length":203,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., March 10, 2026--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial Resistance (AMR) Benchmark Report published by the Access to Medicine Foundation. The score represents the highest rating in the small- and medium-sized enterprise (SME) category, achieved by only one other company in this year’s report. The AMR Benchmark evaluates pharmaceutical companies’ efforts to combat antimicrobial resistance and expand global access to effective treatments.","length":631,"tagName":"p"},{"type":"text","content":""We are honored to be recognized in this important global assessment of the antibiotic treatment landscape, particularly at a time when there is a growing need for new therapies as antibiotic resistance continues to rise across many regions, challenging our ability to treat life-threatening infections effectively," said David Altarac, M.D., Chief Medical Officer of Innoviva Specialty Therapeutics. "Addressing this urgent public health crisis is central to our mission, and we remain committed to developing innovative therapies that target high-priority and difficult-to-treat pathogens."","length":612,"tagName":"p"},{"type":"text","content":...